Moreover, surprisingly EGFR protein expression itself failed as predictive marker to EGFR-targeted antibody-based therapy responses: For example, CRC patients may respond to Cetuximab even without EGFR expression [34] and - vice versa – CRC patients with EGFR-positive tumors do not exhibit higher response rates as compared to those CRC patients with EGFR-negative tumors [40, 41]. Here, EGFR is linked to colorectal carcinoma.